Share >  
Share
Share on Tumblr

Melogliptin

News »

   latest by relevance
No plans to list generics biz as of now: Glenmark
Oct 27, 2010 at 16:25 | Source: CNBC-TV18
Glenmark Pharma reported a net profit of Rs 112 crore as compared to Rs 80.9 crore, a growth of 38.44% on a year-on-year basis. Consolidated net sales rose 23.05% to Rs 741.4 crore from Rs 602.5 crore
Growth prescription: Glenn Saldanha on Glenmark in 2010
Jan 19, 2010 at 19:37 | Source: CNBC-TV18
The recent ruling by the Federal Trade Commission may impact the generics industry. So says Glenn Saldanha, MD and CEO of Glenmark. In an interview with CNBC-TV18, Saldanha spoke about the recent FTC ruling, revenue kickers and out-licensing deals in 2010.
Glenmark expects interest costs to come down in Q3
Oct 30, 2009 at 14:02 | Source: Moneycontrol.com
Glenmark Pharmaceuticals declared its second quarter results for the financial year 2010. The companys Q2 consolidated net profit was down at Rs 80.9 crore versus Rs 117.3 crore and its consolidated net sales were up at Rs 590.3 crore versus Rs 559.7 crore
Expect FY10 topline to grow by 20-25%: Glenmark
Oct 29, 2009 at 15:43 | Source: CNBC-TV18
In an interview with CNBC-TV18, Glenn Saldanha, Managing Director and Chief Executive Officer, Glenmark Pharmaceuticals spoke about the companys results.
Glenmark to raise more funds via stake sale in generic arm
Sep 15, 2009 at 11:43 | Source: CNBC-TV18
Glennmark Pharmaceutical has raised Rs 413.56 crore via qualified institutional placements through the issue of over 1.87 crore shares. The Pharma has no plans to raise any further equity capital in the parent company but would be raising capital via stake dilution Glenmark generics for further debt repayment.
Glenmark to close Melogliptin molecule deal by 2009 end
Jun 24, 2009 at 17:32 | Source: CNBC-TV18
Glenn Saldanha, MD and CEO, Glenmark, said Phase II data of Melogliptin is better than competitors. He said the company is in discussion with various companies to close deal on Melogliptin. "We will be able to close the deal on Melogliptin by CY09 end."

Videos »
No plans to list generics biz as of now: Glenmark
Growth prescription: Glenn Saldanha on Glenmark in 2010
Expect FY10 topline to grow by 20-25%: Glenmark
Glenmark to close Melogliptin molecule deal by 2009 end
Glenmark scales down base biz growth target to about 20%
more »

Photos »

  /  

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window